Primary prophylaxis of <i>Pneumocystis jirovecii</i> pneumonia (PCP) in people with HIV (PWH) and CD4+ counts <200 cells/μL using trimethoprim/sulfamethoxazole (TMP-SMX) is highly effective but often poorly tolerated. Here, CD4 is linked to susceptibility to pneumonia measurement.